Timing in Combination with Radiotherapy and Patterns of Disease Progression in Non-small Cell Lung Cancer Treated with EGFR-TKI

Lung cancer is one of the most common cancers worldwide, with a 5-year survival rate of only 18% for all stages combined. Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases. The discovery of epidermal growth factor receptor (EGFR) mutations has led NSCLC treatment into a new era with tyrosine kinase inhibitor (TKI)-based therapy, which has become a standard of care, achieving a progression-free survival (PFS) of 9-10 months and an overall survival (OS) of 22-30 months [1 –4].

Source: Lung Cancer - December 17, 2019 Category: Cancer & Oncology Authors: Yi Tang, Bing Xia, Xiao Xu, Minna Zhang, Kan Wu, Bing Wang, Shenglin Ma Source Type: research